The Karuna Ganesh Lab: Publications


Ganesh K*, Wu C*, O’Rourke KP, Adileh M, Szeglin B, Wasserman I, Marco MR, Shady M, Zheng Y, Karthous WR, Won HH, Choi SH, Pelossof RA, Barlas A, Pappou E, Elghouayel A, Strong JD, Chen CT, Harris JW, Wiser MR, Nash GM, Guillem JG, Wei IH, Cercek A, Kolesnick RN, Manova-Todorova KO, Saltz LB, DeMatteo RP, Massague J, Romesser PB, Paty PB, Yaeger RD, Clevers H, Berger M, Shia J, Lowe SW, Dow LE, Garcia-Aguilar J, Sawyers CL*, Smith JJ*. A rectal cancer model establishes a platform to study individual responses to chemoradiation. bioRxiv 640193; doi: https://doi.org/10.1101/640193

Wang T, Lee LH, Vyas M, Zhang L, Ganesh K, Firat C, Segal NH, Desai A, Hechtman JF, Ntiamoah P, Weiser MR, Markowitz AJ, Vakiani E, Klimstra DS, Stadler ZK, Shia J. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. Mod Pathol. 2019 Jun 7. doi: 10.1038/s41379-019-0289-6. [Epub ahead of print] PubMed.

Basnet H, Tian L, Ganesh K, Huang YH, Macalinao DG, Brogi E, Finley LW, Massagué J. Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization. Elife. 2019 Mar 26;8. pii: e43627. doi: 10.7554/eLife.43627. PubMed; PubMed Central PMCID: PMC6440742.

Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375. doi: 10.1038/s41575-019-0126-x. Review. PubMed.

Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, Widmar M, Ganesh K, Yaeger R, Cercek A, Weiser MR, Nash GM, Guillem JG, Temple LKF, Chalasani SB, Fuqua JL, Petkovska I, Wu AJ, Reyngold M, Vakiani E, Shia J, Segal NH, Smith JD, Crane C, Gollub MJ, Gonen M, Saltz LB, Garcia-Aguilar J, Paty PB. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncol. 2019 Jan 10:e185896. doi: 10.1001/jamaoncol.2018.5896. [Epub ahead of print] PubMed; PubMed Central PMCID: PMC6459120.

Wasserman I, Lee LH, Ogino S, Marco MR, Wu C, Chen X, Datta J, Sadot E, Szeglin B, Guillem JG, Paty PB, Weiser MR, Nash GM, Saltz L, Barlas A, Manova-Todorova K, Uppada SPB, Elghouayel AE, Ntiamoah P, Glickman JN, Hamada T, Kosumi K, Inamura K, Chan AT, Nishihara R, Cercek A, Ganesh K, Kemeny NE, Dhawan P, Yaeger R, Sawyers CL, Garcia-Aguilar J, Giannakis M, Shia J, Smith JJ. SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance. Clin Cancer Res. 2019 Mar 15;25(6):1948-1956. doi: 10.1158/1078-0432.CCR-18-1726. Epub 2018 Dec 26. PubMed; PubMed Central PMCID: PMC6421131.

Er EE, Valiente M, Ganesh K, Zou Y, Agrawal S, Hu J, Griscom B, Rosenblum M, Boire A, Brogi E, Giancotti FG, Schachner M, Malladi S, Massagué J. Author Correction: Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat Cell Biol. 2019 Mar;21(3):408. doi: 10.1038/s41556-018-0257-2. PubMed.

Er EE, Valiente M, Ganesh K, Zou Y, Agrawal S, Hu J, Griscom B, Rosenblum M, Boire A, Brogi E, Giancotti FG, Schachner M, Malladi S, Massagué J. Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat Cell Biol. 2018 Aug;20(8):966-978. doi: 10.1038/s41556-018-0138-8. Epub 2018 Jul 23. Erratum in: Nat Cell Biol. 2019 Mar;21(3):408. PubMed; PubMed Central PMCID: PMC6467203.

Ganesh K, Massagué J. TGF-β Inhibition and Immunotherapy: Checkmate. Immunity. 2018 Apr 17;48(4):626-628. doi: 10.1016/j.immuni.2018.03.037. PubMed PMID: 29669246; PubMed Central PMCID: PMC6347120. 9: Ganesh K, Shah RH, Vakiani E, Nash GM, Skottowe HP, Yaeger R, Cercek A, Lincoln A, Tran C, Segal NH, Reidy DL, Varghese A, Epstein AS, Sonoda Y, Chi D, Guillem J, Temple L, Paty P, Hechtman J, Shia J, Weiser M, Aguilar JG, Kemeny N, Berger MF, Saltz L, Stadler ZK. Clinical and genetic determinants of ovarian metastases from colorectal cancer. Cancer. 2017 Apr 1;123(7):1134-1143. doi: 10.1002/cncr.30424. Epub 2016 Nov 22. PubMed; PubMed Central PMCID: PMC5360467.

Abu-Zeinah GF, Weisman P, Ganesh K, Katz SS, Dogan A, Abou-Alfa GK, Stein EM, Jarnagin W, Mauro MJ, Harding JJ. Acute myeloid leukemia masquerading as hepatocellular carcinoma. J Gastrointest Oncol. 2016 Jun;7(3):E31-5. doi: 10.21037/jgo.2015.12.01. PubMed; PubMed Central PMCID: PMC4880775.

van Maldegem F, Maslen S, Johnson CM, Chandra A, Ganesh K, Skehel M, Rada C. CTNNBL1 facilitates the association of CWC15 with CDC5L and is required to maintain the abundance of the Prp19 spliceosomal complex. Nucleic Acids Res. 2015 Aug 18;43(14):7058-69. doi: 10.1093/nar/gkv643. Epub 2015 Jun 29. PubMed; PubMed Central PMCID: PMC4538830.

Ganesh K, van Maldegem F, Telerman SB, Simpson P, Johnson CM, Williams RL, Neuberger MS, Rada C. Structural and mutational analysis reveals that CTNNBL1 binds NLSs in a manner distinct from that of its closest armadillo-relative, karyopherin α. FEBS Lett. 2014 Jan 3;588(1):21-7. doi: 10.1016/j.febslet.2013.11.013. Epub 2013 Nov 20. PubMed PMID: 24269683; PubMed Central PMCID: PMC3885797. 13: Ganesh K, Neuberger MS. The relationship between hypothesis and experiment in unveiling the mechanisms of antibody gene diversification. FASEB J. 2011 Apr;25(4):1123-32. doi: 10.1096/fj.11-0402ufm. Review. PubMed.

Ganesh K, Adam S, Taylor B, Simpson P, Rada C, Neuberger M. CTNNBL1 is a novel nuclear localization sequence-binding protein that recognizes RNA-splicing factors CDC5L and Prp31. J Biol Chem. 2011 May 13;286(19):17091-102. doi: 10.1074/jbc.M110.208769. Epub 2011 Mar 8. PubMed; PubMed Central PMCID: PMC3089553.

Conticello SG, Ganesh K, Xue K, Lu M, Rada C, Neuberger MS. Interaction between antibody-diversification enzyme AID and spliceosome-associated factor CTNNBL1. Mol Cell. 2008 Aug 22;31(4):474-84. doi: 10.1016/j.molcel.2008.07.009. PubMed.